Status:
COMPLETED
A Study of the Tumor Microenvironment Affecting the Efficacy of Immunotherapy for Esophageal Cancer
Lead Sponsor:
Renmin Hospital of Wuhan University
Conditions:
Esophageal Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
This study is a retrospective study of clinical specimens. The study subjects were patients with esophageal cancer who received immunotherapy. Tumor tissue specimens surgically removed from patients b...
Eligibility Criteria
Inclusion
- Esophageal cancer patients receiving immunotherapy
- Radical esophagectomy for esophageal cancer at our institution prior to receiving immunotherapy
- Age greater than or equal to 18 years and less than or equal to 75 years old Imaging to assess patient efficacy after cycle 2 immunotherapy (CR/PR, SD/PD according to recist 1.1)
- Pathology Tumor tissue available
Exclusion
- Clinical and pathologic information not available
- Combined history of other malignant tumors
- Unavailability of surgically resected tissue
- Preoperative neoadjuvant therapy
- Radical esophagectomy for esophageal cancer not performed prior to immunotherapy
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2024
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT06219031
Start Date
December 1 2023
End Date
January 1 2024
Last Update
January 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renmin hosptial of Wuhan University
Wuhan, Hubei, China, 430060